Abbott Laboratories announced a Class I recall of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose‑monitoring sensors on February 4 2026, after the U.S. Food and Drug Administration identified a defect that could produce readings lower than actual blood glucose levels.
The recall follows reports of seven deaths and 860 serious injuries linked to the faulty sensors. Abbott’s own data indicate that the deaths were reported worldwide, with no U.S. fatalities, and the injuries were attributed to incorrect glucose readings that could lead to inappropriate insulin dosing.
Prior to this recall, Abbott had already issued a medical‑device correction on November 24 2025 that covered approximately 3 million sensors in the United States, and a July 2025 recall that addressed erroneously high readings in a subset of FreeStyle Libre 3 units. The FDA also issued a warning letter on January 23 2026 citing manufacturing and testing deficiencies related to sensor accuracy.
Abbott has stated that it has identified and resolved the manufacturing issue that caused the sensor error and does not expect significant supply disruptions. The company’s spokesperson emphasized that corrective actions are complete and that the recall is intended to protect patient safety.
Financially, Abbott’s most recent quarterly earnings showed a revenue miss of $11.46 billion versus analyst expectations of $11.80 billion, driven in part by a decline in the Nutrition segment. The company guided for a 2026 full‑year organic sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.55–$5.80, a slight downward revision from prior guidance. The recall could add regulatory costs and potential litigation expenses, but management believes the impact on cash flow will be limited.
The recall underscores the importance of rigorous quality control in Abbott’s diabetes‑care portfolio and may heighten regulatory scrutiny. While the company maintains confidence in its corrective measures, the incident could erode consumer trust and expose Abbott to legal challenges, potentially affecting its market position in the competitive glucose‑monitoring space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.